Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 14, 2019

SELL
$2.67 - $3.65 $1.96 Million - $2.67 Million
-732,774 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$3.05 - $4.34 $3.26 Million - $4.63 Million
-1,067,226 Reduced 59.29%
732,774 $3.08 Million
Q3 2018

Nov 13, 2018

SELL
$1.45 - $6.15 $652,500 - $2.77 Million
-450,000 Reduced 20.0%
1,800,000 $7.83 Million
Q1 2018

May 15, 2018

BUY
$1.25 - $2.65 $2.81 Million - $5.96 Million
2,250,000 New
2,250,000 $4.16 Million

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $751M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track New Leaf Venture Partners, L.L.C. Portfolio

Follow New Leaf Venture Partners, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Leaf Venture Partners, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on New Leaf Venture Partners, L.L.C. with notifications on news.